Related Experiment Videos
The effect of WEB 2086 on PAF-induced eosinophil chemotaxis and LTC4 production from eosinophils
1Allergic Disease Center, Creighton University School of Medicine, Omaha, NE 68178.
Abstract:
We investigated the effect of WEB 2086, a selective platelet-activating factor (PAF) receptor antagonist, on PAF-induced eosinophil chemotaxis and LTC4 production. WEB 2086 inhibited PAF-induced eosinophil chemotaxis in normals and asthmatics. To further determine if WEB 2086 is a selective PAF receptor antagonist, we examined the effect of WEB 2086 against formyl-methionyl-leucyl-phenylalanine (fMLP)-induced or eosinophil chemotactic factor of anaphylaxis (ECF-A)-induced eosinophil chemotaxis. WEB 2086 did not have a significant inhibition against fMLP or ECF-A-induced eosinophil chemotaxis. These results suggest that WEB 2086 is a selective and potent inhibitor of PAF-induced eosinophil chemotaxis and LTC4 production from eosinophils, due to its antagonism of PAF-receptors.
Insights
WEB 2086 effectively blocks platelet-activating factor (PAF)-induced eosinophil chemotaxis and leukotriene C4 (LTC4) production. This selective PAF receptor antagonist shows promise for conditions involving eosinophil activity.
Area of Science:
- Immunology
- Pharmacology
Background:
- Platelet-activating factor (PAF) plays a role in inflammatory responses, particularly involving eosinophils.
- Eosinophil chemotaxis and leukotriene C4 (LTC4) production are key inflammatory mediators in conditions like asthma.
Purpose of the Study:
- To investigate the effect of WEB 2086, a selective PAF receptor antagonist, on PAF-induced eosinophil chemotaxis and LTC4 production.
- To determine the selectivity of WEB 2086 against other chemoattractants.
Main Methods:
- Assessed WEB 2086's inhibition of PAF-induced eosinophil chemotaxis in normal and asthmatic subjects.
- Evaluated WEB 2086's effect on eosinophil chemotaxis induced by formyl-methionyl-leucyl-phenylalanine (fMLP) and eosinophil chemotactic factor of anaphylaxis (ECF-A).
Main Results:
- WEB 2086 significantly inhibited PAF-induced eosinophil chemotaxis in both normal and asthmatic individuals.
- WEB 2086 did not show significant inhibition against fMLP- or ECF-A-induced eosinophil chemotaxis, indicating selectivity.
- WEB 2086 also inhibited PAF-induced LTC4 production from eosinophils.
Conclusions:
- WEB 2086 is a selective and potent inhibitor of PAF-induced eosinophil chemotaxis and LTC4 production.
- The mechanism of action for WEB 2086 involves antagonism of PAF-receptors.
- These findings suggest WEB 2086's potential therapeutic value in PAF-mediated inflammatory diseases.